New award for lisinopril tablets with exelan. Period of performance is FEB 12, 2022 to FEB 11, 2023 with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79722D0005
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 95% complete
IDV ceiling
$40,480,225.15
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Exelan Pharmaceuticals Inc. for Lisinopril tablets with a ceiling of $40,480,225.15 on February 12, 2022. The contract carries no set-aside designation and is structured as a one-year base period running February 12, 2022 through February 11, 2023, with four successive one-year options extending the ultimate completion date to February 11, 2027.

The originating solicitation sought 23 different strengths and package sizes of lisinopril tablets to supply the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service, with estimated annual requirements exceeding 1.5 million bottles. The procurement was issued as a commercial item contract under FAR Part 12. Place of performance includes Exelan's primary manufacturing and distribution facility in Boca Raton, Florida, along with secondary locations in Cary, North Carolina; Summit, New Jersey; and Ottawa, Ontario, Canada, as well as other designated federal delivery locations specified by contracting agencies. The contract falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and PSC code 6505 (Drugs and Biologicals).

Distribution occurs through the VA and DOD pharmaceutical prime vendor programs to serve the identified customer agencies. Evaluation was based on the contractor's ability to provide an uninterrupted supply of the required formulations across all specified strengths and packages.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00021 · Implementation of executive order 14398 addressing DEI discrimination by federal contractors $0
Add Subcontract Plan P00020 · Incorporate 2026/2027 subcontracting plan $0
Exercise an Option P00019 · Exercise option year 4 effective FEB 12, 2026 to FEB 11, 2027 for lisinopril tablets with exelan $0
Add Subcontract Plan P00018 · Incorporate subk plan 4/1/2025 - 3/31/2026 $0
Exercise an Option P00017 · This modification is to exercise option year 3 contract february 12, 2025, to february 11, 2026 on contract 36E79722D0005 for lisinopril tablets. $0
Supplemental Agreement for work within scope P00016 · This modification is issued to incorporate 2 ndcs changes under contract 36E79722D0005, lisinopril tablets. $0
Other Administrative Action P00015 · Administrative point of contact (POC) change $0
Add Subcontract Plan P00014 · This modification is issued to incorporate the approved commercial company-wide subcontracting plan into contract 36E79722D0005 for the period of 04/01/2024 -… $0
Supplemental Agreement for work within scope P00012 · 52.212-4(C) contract terms and conditions - changes update to cost recovery fee (CRF) and submission of quarterly sales reports for 36E79722D0005 exelan… $0
Other Administrative Action P00011 · POC administrative change to brian christensen $0
Exercise an Option P00010 · This modification is issued to exercise the 2ND option year for lisinopril tablets under contract 36E79722D0005 with exelan pharmaceuticals, INC. For the period… $0
Supplemental Agreement for work within scope P00009 · This modification is issued to delete 22 ndcs from contract 36E79722D0005, lisinopril tablets. $0
Other Administrative Action P00008 · POC administrative change for 36E79722D0005. $0
Supplemental Agreement for work within scope P00007 · Lisinopril NDC changes on contract 36E79722D0005. Old ndcs will remain on contract until fully depleted. $0
Supplemental Agreement for work within scope P00006 · On contract 36E79722D0005, NDC changes for fourteen lisinopril ndcs. Old ndcs will remain on contract until fully depleted. $0
Other Administrative Action P00005 · Incorporate contract administrator changes to contract 36E79722D0005. $0
Other Administrative Action P00004 · Incorporation of drug supply chain security act (DSCSA) language $0
Add Subcontract Plan P00003 · This modification is issued to incorporate the approved commercial company-wide subcontracting plan into exelan contract 36E79722D0005 for the period of… $0
Exercise an Option P00002 · Exercise option year 1 effective february 12, 2023 through february 11, 2024 for lisinopril tablets with exelan pharmaceuticals, INC. Prices remain unchanged. $0
Add Subcontract Plan P00001 · Exelan pharmaceuticals, INC. 2022 subcontracting plan. This modification is issued to incorporate the approved commercial company-wide subcontracting plan… $0
Original award $0
Show all 21

Quick answers

Who was awarded contract 36E79722D0005?

36E79722D0005 was awarded to Exelan Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on February 12, 2022.

How much is contract 36E79722D0005 worth?

36E79722D0005's own ceiling is $40,480,225.

Who can order from contract 36E79722D0005?

36E79722D0005 is a single award indefinite delivery contract.

Was contract 36E79722D0005 competed?

The extent of competition for 36E79722D0005 was full and open competition. The government received 3 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV